Study of Cell Transplantation in Medicare Multiple Myeloma Subjects

IRB/UVA Tracking #
20533
Principal Investigator
Leonid Volodin
Contact
Contact Phone
Official Trial Title
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Study Description

The University of Virginia Cancer Center is conducting a study, sponsored by the Center for International Blood and Marrow Transplant Research (CIBMTR), that is offered to adults who are undergoing an allogeneic stem cell transplant as part of their treatment for Multiple Myeloma. The study collects information about Multiple Myeloma. The purpose of this study is to collect information about Multiple Myeloma and to compare outcomes between patients who receive allogeneic hematopoietic cell and patients who receive other standard of care therapies.

You may be able to participate in this study if you are a Medicare beneficiary member, have multiple myeloma, and if you are going to receive an allogeneic stem cell transplant in the UVA. Participation in the study requires additional time during your pre-transplant visit during which you will go over the consent form and have your questions answered.

Majority of your clinical information related to your transplant will be collected directly from your medical chart at UVA. The medical information will be sent to CIBMTR to be combined with other participants’ information, and analyzed. The study will collect data on participants’ health for up to 5 years. Your medical information will be protected and not be stored together with any information that can directly identify you.

The stem cell transplant will be charged to Medicare. You will not receive any additional compensation for participating in this study.

Additional information can be found here: NCT03127761

Please contact uvacancertrials@uvahealth.org if you are interested in participating.

Compensation

You will not receive any additional compensation for participating in this study